HIV

HIV care and its related outcomes in South Carolina were defined by racial disparities, specifically in retention in care, despite efforts to end the HIV epidemic.

New data demonstrated that long-acting cabotegravir was preferable to daily dolutegravir/lamivudine in treatment-naive people living with HIV.

Significant demographic differences were found when evaluating the use of depression services in people living with HIV and depression.

Countries in sub-Saharan Africa could see thousands of deaths from HIV due to cuts to the US President’s Emergency Plan for AIDS Relief (PEPFAR), underscoring the necessity of reinstating the program.

Black men who were identified as sexual minorities were more receptive to long-acting injectable pre-exposure prophylaxis (PrEP) vs on-demand PrEP.

Making pre-exposure prophylaxis (PrEP) more accessible can help to decrease the incidence of HIV in the US.

A model that can estimate the need for pre-exposure prophylaxis (PrEP) in the US can help to clarify use patterns to address HIV in local settings.

The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.

The FDA approval marks the first approval of a type of pre-exposure prophylaxis that would only require 2 treatments per year.

Learning the best type of HIV prevention for those at highest risk can start with conversations about their options, writes Zandraetta Tims-Cook, MD, MPH, AAHIVS

The Trump administration has ended a program seeking a vaccine for HIV, the first in a series of decisions that is leaving vaccine research and expertise behind.

About 40% of people living with HIV in an international survey did not make joint decisions regarding treatment with their provider despite reporting a high amount of trust.

People living with HIV who have taken highly active antiretroviral therapy can have hyperlipidemia predicted in advance by machine learning.

Sleep disorders and mental health complications were more common in adolescents or young adults who had HIV across the globe.

A panelist discusses how the injectable combination of cabotegravir and rilpivirine performed well in the real-world OPERA cohort, with over 95% of patients maintaining virologic suppression. However, adherence to injection schedules remains a challenge, with only 62% receiving injections on time.

The CDC uses molecular cluster detection to find the transmission of HIV that could pinpoint where there are gaps in HIV care.

Patients with HIV can take both their antiretroviral therapy (ART) and treatment to prevent tuberculosis safely to prevent infection and further spread of the virus.

The ability to estimate their last viral load was high among women with HIV living in British Columbia, even in those with adverse sociodemographic factors.

A panelist discusses how the new doravirine and islatravir combination offers an alternative to integrase inhibitor-based therapies, particularly useful for patients with integrase inhibitor resistance or adverse reactions, although clinicians may struggle with determining the ideal patient population.

A panelist discusses how a new drug combination of doravirine and islatravir was compared to a standard bictegravir-based therapy in patients with HIV, showing noninferiority with over 90% of patients maintaining viral suppression without excess toxicity.

These guidelines act as an update to the 2016 guidelines for the use of nonoccupational postexposure prophylaxis (PEP) after exposure to HIV.

Viral suppression in HIV was more likely to be reported in women in Canada who had adherence to their antiretroviral therapy (ART) of 90% or higher.

Correlation to social drivers of health (SDOH) had an important correlation with polysubstance use.

A panelist discusses how the HIV patient population has aged significantly, with the average age in their clinic now exceeding 50 years and expected to soon exceed 65 years, and how these aging patients experience more comorbidities at younger ages than the general population while their HIV becomes easier to manage with simple regimens.